ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

Dramatic Increase In Third World Cancer Rates May Face National, International Organizations: Murphy

September 17, 1982

Funding Opportunities

March 7, 2003

HRT Doesn’t Raise Cancer Risk Following Oophorectomy

October 28, 2005

Six Compounds Carcinogenic, Risk to Humans, CH Subgroup Finds

February 2, 1979

Professional Fundraiser Poses Eight Questions For SU2C 3.

September 19, 2008

Capitol Hill: Senate bill would allow sale of therapies for catastrophic illness after phase I trials.

December 2, 2005